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Saliva is a body fluid of a unique composition devoted to
protect the mouth cavity and the digestive tract. Our high
performance liquid chromatography (HPLC)-electrospray
ionization-MS analysis of the acidic soluble fraction of
saliva from preterm human newborn surprisingly revealed
more than 40 protein masses often undetected in adult
saliva. Wewere able to identify the following proteins: stefin
A and stefin B, S100A7 (two isoforms), S100A8, S100A9 (four
isoforms), S100A11, S100A12, small proline-rich protein 3
(two isoforms), lysozyme C, thymosins 4 and 10, antileu-
koproteinase, histone H1c, and  and  globins. The aver-
age mass value reported in international data banks was
often incongruent with our experimental results mostly be-
cause of post-translational modifications of the proteins,
e.g. acetylation of the N-terminal residue. A quantitative
label-free MS analysis showed protein levels altered in re-
lation to the postconceptional age and suggested coordi-
nate and hierarchical functions for these proteins during
development. In summary, this study shows for the first
time that analysis of these proteins in saliva of preterm
newborns might represent a noninvasive way to obtain pre-
cious information of the molecular mechanisms of develop-
ment of human fetal oral structures. Molecular & Cellular
Proteomics 10: 10.1074/mcp.M110.003467, 1–14, 2011.
Saliva is a body fluid of a very complex and specific com-
position devoted to the protection and well-being of the oral
cavity and, because it is swallowed, of the digestive tract (1).
Protection is ensured by organic and inorganic solutes and
specific peptides and proteins, such as acidic and basic
proline-rich proteins, -amylases, salivary cystatins, histatins,
and statherin (2–5). In a previous study (6), we have estab-
lished that some salivary proteins and peptides reach the
levels typically observed in the adult around 18 years of age.
Encouraged by the noninvasive specimen collection, we ex-
plored the salivary protein composition of at-term and pre-
term newborns, in order to establish the starting point of the
secretion of the proteins and peptides specific of saliva. Our
first study (7) showed that acidic proline-rich proteins secre-
tion started, although at very low levels, at 7 months of
postconceptional age. At this age the level of phosphorylation
of these proteins was low and it increased reaching a value
comparable with that of adults at about one year of age, in
concomitance with the beginning of deciduous dentition. Other
deep differences between human and preterm saliva were how-
ever evident. Highly abundant protein masses detected in pre-
term saliva were undetectable (at the sensitivity level of our MS
apparatus) or at very low level in adult saliva. In a previous study
(8) we identified, by different MS approaches, thymosin 4 (T4)
and thymosin 10 (T10) in preterm newborn saliva and estab-
lished by immunohistochemistry their presence in fetal salivary
glands. This finding let us to suppose that in preterm newborns
these peptides derived from gland secretion (8) whereas the low
levels in adult saliva were mainly of crevicular fluid origin (9). In
another study (10) we were able to elucidate the structure of two
isoforms of the small proline-rich protein 3 (SPRR3, or cornifin
)1 detectable only in preterm saliva.
The present study extends our previous findings and reports
for the first time the identification of other proteins in the acidic
soluble fraction of whole saliva of human preterm newborns.
This goal could only be reached by using a top-down proteomic
platform based on high resolution ESI-MS measurements fol-
lowing chromatographic separation of intact proteins.
The identification of 20 components was achieved by dif-
ferent chemical and enzymatic treatments coupled to low-
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and high-resolution MS and mainly confirmed by high-reso-
lution tandem MS (MS/MS) experiments performed on intact
proteins. Moreover, the relative amounts of these proteins
were determined in 61 different samples of eight preterm
subjects in order to evaluate concentration trends as a func-
tion of postconceptional age. The relative amount of proteins
in whole saliva of preterm newborn was also compared with
whole saliva of at-term newborns and adults.
EXPERIMENTAL PROCEDURES
Ethics Statements—The study protocol and written consent forms
were approved by both the Pediatric Department Ethics Committee
and by the Medical Ethics Committee of the Faculty of Medicine of the
Catholic University of Rome (according to the instructions of the
Declaration of Helsinki). Full written consent forms were obtained
from adult donors and from the parents of the newborns and all rules
were respected.
Reagents and Apparatus—All common chemicals and reagents
were of analytical grade and were purchased from Carlo Erba, (Milan,
Italy), Merck (Darmstadt, Germany), Sigma Aldrich (St. Louis, MO),
and Pierce Biotechnology (Rockford, IL). Low-resolution HPLC-
ESI-MS measurements were carried out by a Surveyor HPLC system
(ThermoFisher, San Jose, CA) connected by a T splitter to a photo-
diode-array detector and an LCQ Deca XP Plus mass spectrometer
(ThermoFisher). The chromatographic column was a Vydac (Hesperia,
CA) C8 with 5-m particle diameter (column dimensions 150  2.1
mm). High-resolution HPLC-ESI-MS/MS experiments were carried
out by an Ultimate 3000 Nano/Micro HPLC apparatus (Dionex,
Sunnyvale, CA) equipped with a FLM-3000-Flow manager module
and coupled to an LTQ Orbitrap XL apparatus (ThermoFisher). A
Dionex C18 column (3-m particle diameter; column dimension 300
m i.d. 15 cm) or a Zorbax 300 SB-C8 (3.5-m particle diameter;
column dimension 1 mm i.d. 15 cm) were used as chromatographic
columns. Matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF)-MS was an Autoflex Brucker Daltonics (Billerica, MA)
apparatus.
Subjects Enrolled, Sample Collection and Treatment—Eight new-
borns (five females, three males) with birth weight between 500 g and
1250 g and 193–217 days of postconceptional age (27–31 weeks),
admitted to the Neonatal Intensive Care Unit of the Faculty of Medicine
of the Catholic University were enrolled for this study. Infants with major
congenital malformations or prenatal infections were excluded from the
study. Sample collection was performed on the same preterm newborn
during several weeks following birth at established time intervals (1 or 2
weeks). If possible, analysis was also performed following discharge
from the neonatal unit during the periodical check visits up to 1 year
follow-up. For ethical reasons, saliva was only collected when sample
collection caused no stress to the newborn. In this way we were able to
collect and analyze 61 saliva specimens from newborns with postcon-
ceptional age ranging between 194 and 545 days.
Moreover, saliva from four at term infants (two females, two males)
born after uncomplicated pregnancies and vaginal delivery and admit-
ted to Policlinico “A. Gemelli” nursery, was studied. Gestational age and
birth weight (Mean  S.D.) were 272  7 days (38  1 week) and
3280  150 g, respectively. These four newborns had no clinical prob-
lems, therefore they were discharged after 3 days of breast-feeding.
Resting whole saliva was also collected with a soft plastic aspirator
at the base of the tongue from 20 informed adult volunteers (42  18
years old, 10 males, 10 females).
After collection, salivary samples were immediately mixed with an
equal volume of 0.2% aqueous trifluoroacetic acid (TFA) (v/v) in ice
bath. After stirring, the acidic supernatant was immediately centri-
fuged at 9000 g for 3 min to remove precipitate and the acidic clear
solution was either immediately analyzed by HPLC-ESI-MS (100 l,
corresponding to 50 l of whole saliva) or stored at 80 °C.
Reversed Phase (RP)-HPLC-ESI-MS Analysis—The following solu-
tions were utilized in low-resolution ESI-MS chromatographic sepa-
rations: (eluent A) 0.056% aqueous TFA and (eluent B) 0.050% TFA in
acetonitrile-water 80/20 (v/v). The applied gradient was linear from
0% to 55% B in 40 min, at a flow rate of 0.30 ml/min. The T splitter
permitted 0.20 ml/min to flow toward the diode array detector and
0.10 ml/min toward the ESI source. The photodiode array detector
was set at a wavelength of 214 and 276 nm. During the first 5 min of
separation eluate was not addressed to the mass spectrometer to
avoid source contamination and instrument damage because of the
high salt concentration. Mass spectra were collected every 3 ms in
the positive ion mode. MS spray voltage was 4.50 kV and capillary
temperature was 220 °C.
High-resolution nano-HPLC-ESI-MS/MS experiments were per-
formed by using the following eluents: (A) 0.05% (v/v) aqueous TFA
and (B) 0.05% (v/v) TFA in acetonitrile. The applied gradient was 0–4
min 5% B, 4–34 min from 5% to 50% B (linear), 34–64 min from 50%
to 90% B (linear), at a flow rate of 4.5 l/min. High-resolution positive
MS/MS spectra were collected in full scan using the lock mass for
internal mass calibration (polydimethyl cyclosiloxane, 445.1200 m/z)
with the resolution of 60,000 and 30,000, respectively, and m/z range
from 350 to 2000. In data-dependent acquisition mode the three most
intense multiply charged ions were selected and fragmented by using
collision induced dissociation (35% normalized collision energy) and
spectra were recorded. Alternatively, fragmentation was carried out
under the same conditions on selected multiply charged ions corre-
sponding to specific protein masses. Tuning parameters were: cap-
illary temperature 220 °C, source voltage 2.4 kV, capillary voltage 26
V, tube lens voltage 245 V.
MALDI-TOF-MS Analysis—For MALDI-TOF-MS analysis, samples
were dissolved in 0.1% aqueous TFA and the solution treated with a
C-18 ZipTip pipette tip (Millipore, Billerica, MA) following the manu-
facturer indications including a wash with 0.1% TFA and elution with
0.1% TFA/acetonitrile (1:1, v/v). The desalted solution was mixed 1:1
(v/v) with saturated solutions of R-cyano-4-hydroxycinnamic acid in
acetonitrile/water (50:50, v/v) containing 0.1% TFA. Aliquots of 1 l of
the mixture were spotted onto the stainless steel target of the MALDI
instrument. The calibration was performed using peptide calibration
standards (angiotensin I and II, substance P, and bombesin, m/z
range 1000–3150 Da). Positive MALDI spectra were acquired in either
linear or reflectron mode with a pulsed nitrogen laser (337 nm). In
linear mode an acceleration voltage of 20 kV, a detector gain voltage
of 1300 V, a pulsed ion extraction time of 350 ns and a laser
frequency of 5 Hz were applied. In the reflectron mode an acceler-
ation voltage of 19 kV, a detector gain voltage of 1400 V, a pulsed
ion extraction time of 150 ns, and a laser frequency of 5 Hz were
applied. Mass spectra were acquired over the mass range of 700–
6000 Da with the low mass cut-off of 500 Da and 400 scans were
averaged for each spectrum.
Preparative RP-HPLC Purification of the Proteins Detectable in
Whole Saliva of Preterm Newborns—Semipreparative RP-HPLC was
utilized in order to purify the proteins detected in whole saliva of
preterm newborn and/or to collect peptide fragments from trypsin
digest (see in the following sections). Acidic solution from preterm
saliva (200 l or more, when available) or tryptic digest were purified
on a Surveyor Plus LC system (ThermoFisher) equipped with a PDA
detector set at 214 and 280 nm. The column was a Vydac C8 with 5
m particle diameter (column dimensions 250  4.6 mm). Eluent A
was 0.056% aqueous TFA and eluent B was 0.050% TFA in aceto-
nitrile-water 80/20 (v/v). The applied gradient was linear from 0% to
55% B in 40 min, at a flow rate of 0.90 ml/min. Fractions were
collected in concomitance with the peak exit. The content of any
The Salivary Proteome of Preterm Human Newborns
10.1074/mcp.M110.003467–2 Molecular & Cellular Proteomics 10.1
purified fraction was checked by using HPLC-ESI-MS procedures
described in the previous sections. Fractions with similar content
obtained from different HPLC separation were sometimes pooled.
Several fractions resulted to contain more than one protein. They
were used for enzymatic and chemical treatments as described in the
following sections without further purification.
Automated Edman Sequencing—Protein and peptide sequencing
was carried out on the purified protein or peptide with a Procise 610A
Protein Sequencer (Applied Biosystems, Foster City, CA). Sequenc-
ing was carried out by classical Edman degradation according to
manufacturer’s instructions.
Enzymatic Dephosphorylation—Freeze-dried powder of the puri-
fied protein or of protein mixtures (ca. 50 g) was dissolved in 100 l
of 0.2 M Tris-HCl (pH 8.6) and 40 l of calf intestinal alkaline phos-
phatase (1 EU/l, Roche-Boehringer, Mannheim, Germany) were
added. Incubation was carried out at 37 °C and after 40 min the
solution was centrifuged at 8000  g for 5 min, and the supernatant
immediately analyzed by RP-HPLC-ESI-MS.
Removal of N-Terminal Acetylation—Freeze-dried powder of the
purified protein or of protein mixtures was incubated in the presence
of 25% TFA at 55 °C for 1h and the solution was analyzed by RP-
HPLC ESI-MS.
Reduction and Alkylation of Cysteine Residues—Freeze-dried pow-
ders of the purified proteins or protein mixtures were dissolved at a
concentration about 5 mol/L in 100 l of 100 mmol/L Tris-HCl buffer
pH 7.5 containing 5 mmol/L dithiotreitol. The solution was incubated
at 100 °C for 5 min and subsequently at 50 °C for 15 min. After
incubation, 1 l of dimethylsulfoxide and 13 l of 0.4 mol/L 4-vi-
nylpyridine in methanol 95% were added at room temperature to the
solution. The solution was kept in the dark at room temperature for
3 h. Reaction was stopped by adding 115 l of 0.2% TFA in H2O. The
solution was analyzed by RP-HPLC ESI-MS.
Trypsin Digestion—50 g of the freeze-dried powder of the puri-
fied protein or protein mixture was dissolved in 250 l of 0.5 M
ammonium hydrogen-carbonate (pH 8.0) and digested at 37 °C
under stirring for 5 h by adding 10 units of immobilized trypsin
(Pierce Biotechnology, Rockford, IL). After incubation the solution
was centrifuged at 8000  g for 5 min and the supernatant lyoph-
ilized and stored at 80 °C.
Data Analysis—Deconvolution of averaged ESI mass spectra was
automatically performed either by the software provided with the
Deca-XP instrument (Bioworks Browser) or by MagTran 1.0 software
(11). Experimental mass values were compared with theoretical av-
erage mass (Mav) values available at the Swiss-Prot data bank (http://
us.expasy.org/tools). Proteins and derivatives were identified as de-
scribed in the result section.
The relative abundances of proteins and derivatives were determined
by measuring the XIC peak area and relating it to 1.0 ml of whole saliva.
Under identical experimental conditions this value is linearly propor-
tional to peptide concentration and it can be used with confidence to
monitor relative abundances (12). In the determination of XIC peak area
a correct choice of the m/z values for protein detection is necessary,
avoiding m/z potentially overlapping with ESI spectra of other close-
eluting proteins in crowded chromatographic elution ranges (see “Re-
sults”). The window for all them/z values chosen was in a range of 0.5
m/z. The percentage error of the measurements was less than 10%.
Pearson r coefficient was used to evaluate linear correlations among the
(XIC peak area/ml of whole saliva) of different proteins. Data obtained
from the analysis of trypsin digestion products by nano-HPLC-ESI-
MS/MS LTQ Orbitrap XL apparatus were elaborated by the Proteome
Discoverer 1.0 program, based on SEQUEST cluster as search engine
(University of Washington, USA, licensed to Thermo Electron Corp., San
Jose, CA) against Swiss-Prot human proteome (March 10th, 2010 re-
lease; uniprot-taxonomy-9606-AND-reviewed-yes.fasta; 34756 nonre-
dundant protein sequences). For peptide matching the following limits
were used: Xcorr scores greater than 1.5 for singly charged peptide ions
and 2.0 and 2.5 for doubly and triply charged ions, respectively, one
missed cleavage sites. Different searches were carried out allowing the
recognition of various post-translational modifications (PTMs). Precur-
sor mass search tolerance was set to 10 ppm and fragment mass
tolerance was set to 1.5 Da.
RESULTS
Top-Down HPLC-ESI-MS Analysis of Whole Saliva of Pre-
term Newborns—The acidic soluble fraction of whole saliva of
preterm human newborns (195–220 days of postconceptional
age) showed an HPLC-ESI-MS total ion current profile very
FIG. 1. Comparison between the total
ion current HPLC-ESI-MS profiles of
the acidic soluble fraction of whole sa-
liva from an adult (34 years, panel A)
and a preterm newborn (226 days of
postconceptional age, Panel B). In the
adult profile, the elution ranges of the
main families of secretory salivary pro-
teins are reported (a-PRPs, b-PRPs, G-
PRPs: acidic, basic, glycosylated proline-
rich proteins. HSA: human serum
albumin). In the preterm profile the num-
bers 1–41 show the chromatographic po-
sitions of the proteins, listed according to
Tables I and II. Numbers 40 and 41 (not
reported in Tables I and II) refer to -glo-
bin and -globins, respectively. The in-
dent in panel B shows, for example, the
ESI spectrum of the protein eluting be-
tween 40.0 and 40.8 min, which after de-
convolution displayed an experimental
Mav of 10834  2 Da and that was iden-
tified as S100A8. Whole saliva (WS), NL,
normalization level; RT, retention time.
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different from that of the adult (Fig. 1, A and B). In the profile
of saliva from adult (Fig. 1A) the principal chromatographic
peaks corresponded to peptides and proteins specific of sal-
ivary glands (acidic and basic proline-rich proteins, statherin,
histatins, and S-type cystatins) and to their fragments and
derivatives (13–18). In the profile of saliva from preterm new-
borns (Fig. 1B) proteins characteristic of adult whole saliva
were either absent or present in very low relative amounts. On
the contrary, various proteins almost absent in adult whole
saliva were consistently detected in whole saliva of preterm
newborns, as evidenced by deconvolution of their ESI-MS
spectra. For example, the indent of Fig. 1 shows the ESI mass
spectrum of the protein, identified as S100A8, eluting be-
tween 40.0 and 40.8 min, which following deconvolution dis-
played an experimental average mass (Mav) value of 10834 
2 Da. The numbers assigned to specific elution positions in
the B profile correspond to the protein masses listed in Tables
I and II. The numbers 40 and 41 were assigned to -globin
(Swiss-Prot Number: P69905; Mav 15128  3 Da) and -glo-
bins (P69891/2; Mav A: 16009  3 Da; G: 15995  3 Da)
(Table III). Table I shows the 25 Mav values of the salivary
proteins observed with high frequency ( 50%) in 61 speci-
mens of whole saliva collected at different postconceptional
age from eight preterm newborns. Those detected with low
frequency (10%–50%) are reported in Table II. In Tables I and
II protein elution times are also reported.
The detection of -globins required sometimes the modifi-
cation of the elution gradient because of overlapping with
heterogeneous glyco-proteins, which generated crowded ESI
spectra.
Identification of the Proteins Detected in Saliva of Preterm
Newborns—Because of the small sample volume available,
the most demanding task of this study was the characteriza-
tion of the proteins reported in Tables I and II. The Mav value
of the intact protein, even if determined with good accuracy
(in our apparatus  0.02%), is obviously not enough for the
definitive identification. The experimental scheme of the top-
down proteomic approach followed in this study is described
in the flow chart of Fig. 2. Preparative RP-HPLC on some
samples of preterm newborn saliva allowed several chro-
matographic fractions to be collected. Fractions were ana-
lyzed by HPLC-ESI-MS in order to check protein content,
and, because of similar polarity, more than one protein/pep-
tide in each chromatographic fraction was often detected.
Fractions showing a predominant protein were lyophilized and
an aliquot subjected to automated Edman sequencing. It was
possible to sequence only lysozyme and antileukoproteinase
whereas results of the other proteins suggested a blocked
N-terminal residue. Some of the chromatographic fractions
were subjected to reduction and alkylation with vinyl-pyridine,
others were treated to remove the N-terminal acetyl group,
others were submitted to the action of phosphatases, follow-
TABLE I
Proteins masses (Da) detected with high frequency (more than 50%) in the HPLC-ESI-MS profile of saliva from preterm newborns, and their
attributions, Swiss-Prot Numbers, elution times and frequencies. Experimental error of the average mass:  0.02%
Mav exp. Identity Swiss-Prot number Elution time (min) Frequency (8 subjects) Frequency (61 samples)
1 4936.5 Thymosin 10 P63313 19.9–21.7 8/8 60/61
2 4963.5 Thymosin 4 P62328 18.1–18.9 8/8 60/61
3 9956 Non identified (n.i.) 31.7–32.3 8/8 57/61
4 10651 n.i. 32.9–33.5 8/8 44/61
5 10765 n.i. 31.2–32.0 8/8 56/61
6 10834 S100A8a P05109 40.0–40.8 8/8 61/61
7 10875 n.i. 32.2–32.8 8/8 34/61
8 11006 Stefin A P01040 31.4–32.2 8/8 61/61
9 11049 n.i. 32.1–32.9 8/8 56/61
10 11182 Stefin B P04080 32.6–33.4 8/8 48/61
11 11368 S100A7a (D27 var.) P31151 36.7–37.3 8/8 48/61
12 11382 S100A7a (E27 var.) P31151 36.6–37.2 8/8 44/61
13 11710 Antileukoproteinase P03973 25.8–26.6 8/8 55/61
14 12689 S100A9a P06702 41.8–42.6 8/8 59/61
15 12769 S100A9a P06702 41.8–42.6 8/8 59/61
16 13153 S100A9a P06702 41.5–42.3 8/8 44/61
17 13233 S100A9a P06702 41.5–42.3 8/8 42/61
18 13274 n.i. 41.2–42.0 8/8 48/61
19 13456 n.i. 41.1–41.9 8/8 55/61
20 14694 Lysozyme P61626 35.2–36.0 8/8 58/61
21 14990 n.i. 35.0–35.8 8/8 31/61
22 15079 n.i. 34.2–35.0 8/8 43/61
23 17239 SPRR3 (isof. 17 kDa) A5YKK8 27.0–27.8 8/8 (7/8) 49/61 (41/61)
“ 18065 SPRR3 (isof. 18 kDa) Q9UBC9 27.2–28.0 (5/8) (28/61)
24 22365 Histone H1c P16402 34.0–34.5 8/8 52/61
25 24652 n.i. 44.4–45.2 8/8 46/61
a For the nomenclature of S100 proteins see Ref. 19.
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ing the procedures described in the Experimental Procedures
section. After these reactions, an aliquot of the modified pro-
teins was analyzed by HPLC-ESI-MS in order to measure the
mass variation. Another approach for protein characterization
was based on trypsin digestion of purified proteins and anal-
ysis of digestion products by nano-HPLC-ESI-MS/MS using
the high-resolution LTQ Orbitrap XL apparatus. Many MS/MS
fragmentation spectra were manually analyzed. This ap-
proach sometimes resulted in plausible protein identification.
However, often theoretical Mav values deduced from the se-
quence reported in the data bank did not correspond to the
experimental one. For some proteins the hypothesis of loss of
the N-terminal methionine residue followed by N-terminal
acetylation resulted in a good correspondence of the theoret-
TABLE II
Protein masses detected with low frequency (between 10–50%) in the HPLC-ESI-MS profile of saliva from preterm newborns, and elution times
and frequencies. Experimental error of the average mass:  0.02%
Mav exp. Identity Swiss-Prot number Elution time (min) Frequency (8 subjects) Frequency (61 samples)
26 7806 n.i. 20.2–21.7 7/8 17/61
27 7867 n.i. 20.2–21.7 7/8 17/61
28 10444 S100A12 P80511 39.8–40.2 8/8 20/61
29 11652 S100A11 P31949 42.4–43.1 4/8 15/61
30 13780 n.i. 39.0–39.7 6/8 24/61
31 16001 n.i. 27.0–27.7 7/8 18/61
32 17803 n.i. 36.0–36.8 5/8 8/61
33 18420 n.i. 35.8–36.6 6/8 15/61
34 20206 n.i. 37.6–38.1 4/8 8/61
35 20930 n.i. 33.4–33.8 7/8 15/61
36 22698 n.i. 36.5–37.3 8/8 17/61
37 22776 n.i. 36.5–37.3 8/8 16/61
38 24904 Peroxiredoxin 6 (?) P30041 39.6–40.4 6/8 14/61
39 27050 n.i. 26.4–27.0 3/8 7/61
TABLE III
Different experimental approaches carried out for the identification of the proteins listed in Table I and II and post-translational modifications
characterized
A, high resolution MS/MS of the intact protein; B, coincidence with standards; C, N-terminal Edman sequencing; D, peptide mass fingerprint
(trypsin) by MALDI-TOF-MS and/or by ESI-MS; E, MS/MS of the trypsin digest; F, cysteine alkylation by vinyl-pyridine; G, removal of N-terminal
acetyl group; H, phosphatase treatment.
Identity N-term loss N-term acetyl. Other Exp appr. Mav exp.a Mav theor.b Mav theor.c
1 Thymosin 10 M Yes A,B 4936.5 4936.5 4936.5
2 Thymosin 4 M Yes A,B 4963.5 4963.5 4963.5
6 S100A8 - No A 10834 10834 10834
8 Stefin A - No A,D 11006 11006 10875
10 Stefin B - Yes A 11182 11182 11182
11 S100A7 (D27 var.) M Yes A 11368 11368 11326
12 S100A7 (E27 var.) M Yes A 11382 11382 11382
13 Antileukoproteinase - No 8 S-S A,C 11710 11710 11710
14 S100A9 MTCKM Yes A,D,E 12689 12689 -
15 S100A9 MTCKM Yes Phos G,H 12769 12769 -
16 S100A9 M Yes A,D,E 13153 13153 13111
17 S100A9 M Yes Phos G,H 13233 13233 13191
20 Lysozyme - No 4 S-S C,F 14694 14694 14694
23 SPRR3 (17 kDa) M Yes 7 cys D,E,F,G 17239 17239 17328
SPRR3 (18 kDa) M Yes 8 cys D,E 18065 18065 18154
24 Histone H1c ? ? ? D 22365 ? 22260
28 S100A12 M No A 10444 10444 10444
29 S100A11 M Yes A 11651 11651 11740
38 Peroxiredoxin 6 (?) - - - 24904 24904 24904
40 -globin M - B,D,E 15128 15128 15128
41 -globinsd M - B,D,E 16009 16009 16009
a Experimental error of the average mass:  0.02%.
b Theoretical average mass computed considering the PTMs reported in the table.
c Theoretical average mass available in Swiss-Prot data-bank (in italics when the theoretical Mav reported in Swiss-Prot did not correspond
to the experimental).
d Only the average mass of A globin is reported. The Mav of G globin is 15995 Da.
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ical Mav with the experimental one. Protein structures were
definitely confirmed by submitting intact protein to high-res-
olution nano-HPLC-ESI-MS/MS experiments (Fig. 2), per-
formed on the most abundant ions. Sometimes this procedure
provided an MS/MS fragmentation spectrum rich enough to
be manually compared with the theoretical spectrum gener-
ated by the MS-Product program available at the Protein-
Prospector site (http://prospector.ucsf.edu/prospector/mshome.
htm). Structures were assumed as correct if the experimental
fragments with a relative abundance higher than 10% were
present in the theoretical fragmentation spectrum with 0.03 Da
fragment mass tolerance (see Supplemental Data).
Table III lists the experimental and theoretical mass values,
the number of accessible cysteins, the proposed PTMs,
and the methodologies utilized to establish protein identity.
Proteins with Mav values corresponding to the values avail-
able in Swiss-Prot data bank were T4 and T10, S100A8
(calgranulin A; for S100 nomenclature see reference (19)),
stefin B, lysozyme C, S100A12 (calgranulin C), antileukopro-
teinase, peroxyredoxin 6 (this last pending for a definitive
characterization), -globin and -globins. The protein with a
Mav 11,006  2 Da was identified as stefin A with an addi-
tional N-terminal methionine residue (see Supplemental Data)
with respect to the isoform reported in Swiss-Prot (Mav
10,875 Da). We detected just following the stefin A peak
(Table I) a protein with an experimental mass of 10,875 2 Da
but the MS/MS fragmentation spectrum of the intact protein,
even poor, did not correspond to the theoretical fragmenta-
tion values expected for stefin A missing N-terminal methio-
nine. S100A7 (psoriasin) was detected in two isoforms, one
FIG. 2. Flow chart of the top-down
strategy applied in this study. The ex-
perimental flow is described by solid ar-
rows, lines, and boxes. Steps in dashed
boxes connected by dashed arrows al-
low the unambiguous protein identifica-
tion, which requires the correspondence
of experimental Mav with that one of the
structure hypothesized and the coinci-
dence between experimental and theo-
retical MS/MS spectra (within the exper-
imental error). Detailed information on
each characterized protein is reported in
Table III and in Supplemental data.
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(Mav 11,382  2 Da) corresponding to the S100A7 variant
reported in Swiss Prot data bank. The other (Mav 11,368  2
Da), which was the most abundant, corresponded to the
variant E273D. Both S100A7 variants were found to be sub-
mitted to N-terminal acetylation following the loss of the ter-
minal methionine. The Mav values of the other proteins re-
ported in Table III were in agreement with different PTMs not
reported in the data banks. S100A9 (calgranulin B) was de-
tected in four isoforms already characterized by other authors
in human granulocytes (20). Two isoforms (Mav 13,153  2
and 13,233  2 Da), which could be defined as long-types,
were found to be acetylated following loss of the N-terminal
methionine residue and differed from each other in phospho-
rylation of the penultimate threonine residue of the sequence
(Thr112). The other two isoforms (Mav 12,689  2 and
12,769  2 Da), defined as short-types, were found to be
acetylated following the loss of the five N-terminal amino acid
residues (MTCKM) and differed in the phosphorylation of the
same residue of the long-types (Thr108). S100A11 (calgizzarin)
was also found to be acetylated at the N-terminal residue
following methionine loss (PTM not available in Swiss-Prot
data bank). In a previous study (10) we were able to establish
that the same PTMs (methionine loss and N-terminal acety-
lation) were responsible for the observed Mav values of the
two isoforms of SPRR3. The isoform with Mav 18,065  3 Da
differed for the insertion of a further octapeptide repeat (GCT-
KVPEP) to the five identical repeats present in the 17,239  3
Da isoform and for the presence of Leu at positions 148,
instead of Val at the corresponding position 140 of the shorter
isoform (10). Three subjects (out of 8) were homozygous for
the 17,239  3 Da isoform, one was homozygous for the
18,065  3 Da isoform, and four subjects were heterozygous.
No polymorphism was observed for the other salivary compo-
nents of preterm newborns (except for  globin, which was
detected, obviously, as A and G isoforms). Tentative identifi-
cation of the protein with Mav 22,365  4 Da with histone H1c
(histone H1.3) was based on analysis of the tryptic digestion
mixture obtained from the purified protein. Data analysis by
Proteome Discoverer attributed three peptides to histone H1c,
and this assignment was also manually checked. The three
fragments corresponded to the sequences 34–46, 65–75, and
140–148 of the protein, two present in other histones, and one
(fr. 140–148) specific for histone H1c. However, the theoretical
Mav of histone H1c is 22,219 Da, 146  4 Da less than the
experimental value. Different isoforms of H1 histone have been
detected in the spleen of adult subjects (21). Thus, we may
hypothesize either that the preterm newborn protein could be
an unknown variant of histone H1c or that not characterized
PTMs are present in the mature protein. Tentative identification
of peroxiredoxin 6 was only based on the detection in saliva of
preterm infants of a peptide corresponding to the fragment 1–32
of the intact protein. Therefore, this protein is still pending for a
definitive identification. Detailed information on the results of the
experiments performed to characterize proteins and PTMs re-
ported in Table III is available in Supplemental Data.
Some other protein masses (not reported) were sporadically
detected in whole saliva of preterm newborns and some
masses, probably pertaining to peptide fragments of larger
proteins, were also detected. Moreover, the (small) precipitate
formed during the acidic treatment of whole saliva might
contain some other proteins/peptides not detectable in the
adult. Their characterization will require further studies.
Determination of Protein Relative Amount as a Function of
Preterm Postconceptional Age—To study the time course of
the identified proteins, HPLC-ESI-MS analyses of samples
collected at different postconceptional age (from 194 to 545
days) from eight newborns, for a total of 61 samples, were
carried out. The relative amounts of each protein were estab-
lished, as previously reported (6), by using the area of the
eXtracted Ion Current (XIC) peaks and relating it to 1 ml of
whole saliva. Quantitative analysis is reported only for the 25
proteins with higher frequencies in the 61 samples listed in
Table I. The multiply charged ions selected for XIC search of
each protein are reported in Table IV.
Fig. 3 shows the mean values of the ratio (XIC peak area)/
(ml of whole saliva (WS)) computed in three ranges of
postconceptional age, i.e. 194–235 days (n  26), 236–290
days (n  21), and 291–545 days (n  14) for all the 25
proteins. The values reported for SPRR3 correspond to the
sum of the two isoforms. In the heterozygous, the XIC peak
areas of the two isoforms were always very similar.
Even though the values reported in Fig. 3 do not correspond
to absolute concentration values, because ESI efficiency dif-
fers between proteins, they suggest that concentrations of the
proteins were markedly different. In previous studies, we cor-
related the values of the XIC peak area of T4 and T10 to their
concentration (8, 9). The mean concentration of T4 in saliva
of preterm newborns with 194–235 days of postconceptional
age was about 1 mol/L, and that one of T10 was about four
times lower. Because of the high structural similarity of iso-
forms and variants, data reported in Fig. 3 suggest that con-
centration of the D27 variant of S100A7 is at least three times
higher than the E27 variant.
In order to compare the concentration variation over time
of the various proteins reported in Table I, quantitative data
obtained in the 61 samples were normalized to the highest
value determined for each protein (Fig. 4). Fig. 4 shows that
concentration of the majority of the proteins decreased,
even though with different slope. For instance, although
stefin A (panel 8) concentration showed a fast decrease
from 195 days of postconceptional age, S100A8 (panel 6)
decrease was slower. The unidentified protein with Mav
24,652  5 Da (panel 25) and S100A7 (D27) (panel 11)
showed low concentration values immediately following
birth followed by a fast increase within 1 or 2 weeks up to
maximum of concentration. Thereafter, concentration de-
creased and reached the minimal levels around 260–280
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days of postconceptional age (corresponding to the normal
term of delivery). Panel 12, which shows data of S100A7
(E27), is compressed because of three high values detected in
one subject. However, the shape is similar to that one of
S100A7 (D27) isoform, but with values significantly lower. Fur-
ther evidence from Fig. 4 is that concentration of all the proteins
reached the minimal levels in correspondence with the normal
term of delivery, sometimes disappearing, at the sensitivity level
of the MS apparatus.
Fig. 4, showing the values measured in the 61 samples,
does not allow the striking differences existing among sub-
jects to be appreciated. Differences are evident from the large
bars of the standard deviations of Fig. 3. The high interindi-
vidual variability becomes clear from Fig. 5, where the values
of six selected proteins measured in three subjects are re-
ported up to 290 days of postconceptional age. Ratios of (XIC
peak area)/(ml of WS) reported in Fig. 5 were normalized with
respect to the highest value determined in each subject in the
FIG. 3. Mean values of the ratios
(XIC peak area)/(ml of WS) calculated
for the 25 proteins detected in saliva
of preterm newborns. Mean values re-
fer to three groups of saliva samples
subdivided according to postconcep-
tional age of preterm newborns: 194–
235 (n 26), 236–290 (n 21), 291–545
days (n 14). Bars correspond to stand-
ard deviation values. SPRR3 data refer
to both isoforms. WS: whole saliva.
TABLE IV
Charge of the ions utilized for the determination of the XIC peak area of the 25 proteins of Table I and parameters expressing concentration trend
over time of each protein in the population investigated. Experimental error of the average mass:  0.02%. Ratios between the mean of (XIC
peak area)/(ml of whole saliva) values (reported in Fig. 3) measured in three different postconceptional age (PCA) ranges: 194–235, 236–290,
and 291–545 days of postconceptional age
Mav exp. Identity Charge of ions Apex (PCA) (m 236–290)/(m 194–235) (m 291–545)/(m 236–290)
1 4936.5 Thymosin 10 From 3 to 5 195 0.46 0.15
2 4963.5 Thymosin 4 From 3 to 5 140–160
a 0.48 0.12
3 9956 n.i. From 6 to 9 195–210 0.46 0.12
4 10651 n.i. From 8 to 11 195 0.25 0.05
5 10765 n.i. From 8 to 11 195 0.39 0.22
6 10834 S100A8 From 8 to 11 195 0.73 0.12
7 10872 n.i. From 8 to 11 195–210 0.16 0.02
8 11006 Stefin A From 8 to 11 195–210 0.45 0.25
9 11049 n.i. From 8 to 11 195 0.44 0.00
10 11182 Stefin B From 7 to 10 195–210 0.32 0.03
11 11368 S100A7 (D27) From 8 to 11 210–240 0.89 0.11
12 11382 S100A7 (E27) From 7 to 10 210–240 1.04 0.05
13 11710 Antileukoproteinase From 6 to 9 205–220 0.54 0.31
14 12690 S100A9 short From 9 to 13 195–220 0.58 0.13
15 12770 S100A9 short (phos) From 9 to 13 195–220 0.63 0.18
16 13155 S100A9 long From 10 to 14 195–205 0.27 0.05
17 13235 S100A9 long (phos) From 10 to 14 195–205 0.27 0.09
18 13274 n.i. From 10 to 14 195–220 0.65 0.15
19 13461 n.i. From 10 to 14 210–240 0.94 0.13
20 14694 Lysozyme From 8 to 12 210–240 1.00 0.40
21 14990 n.i. From 12 to 16 195 0.41 0.06
22 15079 n.i. From 12 to 16 195–220 0.45 0.02
23 17239 SPRR3 From 12 to 17 195 0.19 0.09
18065
24 22365 Histone H1c From 16 to 22 195–220 0.72 0.22
25 24652 n.i. From 14 to 20 230–260 2.50 0.04
a Value from Ref. (8).
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temporal range considered, and therefore they are different
from those reported in Fig. 4. Fig. 5 clearly shows different
trends of decrease, some almost linear (i.e. T4), others with
exponential-like shapes, but with different slopes (i.e. stefin B
and the not identified protein with a Mav of 10,651  2 Da),
others characterized by a sharp decrease following a constant
apex period (i.e. short isoform of S100A9 and SPRR3), and
others, such as S100A7 (D27), by a biphasic trend. Interest-
ingly, Fig. 5 shows that the decrease of concentration of each
protein showed similar shapes in the different subjects, but it
was often phase shifted.
Because of high interindividual variability temporal changes
of the different proteins varied markedly in the 8 subjects.
Table IV shows the postconceptional age ranges correspond-
ing to the maximum concentration observed for each protein.
When the level measured at the lowest postconceptional age
was the highest, it was assumed that maximum concentration
occurred before 195 days of postconceptional age. In order to
find a parameter that could give for each protein a rough
estimate of the concentration trend over time in the popula-
tion investigated, we calculated the ratio between the mean
concentration values shown in Fig. 3. The results reported in
Table IV suggest in some cases time-coordinate functions,
such as for stefin A and B whose decrease was similar, in
other hierarchical functions, such as for S100A7, whose in-
crease followed that of many other proteins.
Fig. 6 shows the correlation coefficients (Pearson r) com-
puted among all the proteins of Table I. Because of the size of
our sample (n  61), r values greater than 0.400 indicate a
level of significance better than p  0.001. Fig. 6 shows
several clusters of high significant correlations, including the
majority of S100 proteins, stefins, SPRR3, and some uniden-
tified proteins. For its particular biphasic trend, S100A7
showed less significant correlations with the other proteins.
Antileukoproteinase, lysozyme, and histone H1c showed low
significant correlations. The unidentified protein with Mav
24,652  5 Da showed a significant correlation only with
lysozyme. Interestingly, although T10 correlation with many
proteins of the list was highly significant, the same was not
observed for T4. Interestingly, the two peptides showed not
very high significant correlation each other. The highest cor-
relation values (higher than 0.93) were observed between the
two S100A9 isoforms and their phosphorylated counterparts,
between S100A8 and S100A9 short type, as well as between
SPRR3, stefin A, stefin B and the unidentified protein with
Mav 10,651  2 Da.
FIG. 4. Ratios (XIC peak area)/(ml of
WS) of the 25 proteins listed in Table I
normalized to highest value deter-
mined for each protein in the 61 sam-
ples plotted as a function of postcon-
ceptional age. SPRR3 data refer to both
isoforms. PCA, postconceptional age.
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Extensive quantitative analysis of the proteins reported in
Table II was not carried out, principally because of their low
frequency. They were usually detectable in the samples in the
range of 194–240 days of postconceptional age, disappear-
ing in the total ion current profile at higher postconceptional
age. This observation suggests that numerous other different
proteins are probably present in fetal mouth during a temporal
period preceding the one investigated in this study, with a
maximum of expression occurring before 6 to-7 months of
postconceptional age.
Comparison of the Salivary Protein Patterns of At-Term New-
borns with Adults—As shown in Fig. 4, concentration of all the
proteins detected in this study decreases in the range 195–280
days of postconceptional age reaching a value up to two orders
of magnitude lower than the maximum measured. For all the
proteins reported in Tables I and II the mean values measured in
the range 270–280 days of postconceptional age (considered
as the normal delivery time) corresponded perfectly to the mean
values measured in whole saliva of at term newborns (n  4).
The mean values measured following 350 days of postconcep-
tional age were very similar to those measured in adult whole
saliva (n  20). Often the protein was not detectable at all in
adult whole saliva, even by XIC search, at the sensitivity level of
our HPLC-MS apparatus. Statistical analysis of all the data
collected did not disclose gender related differences.
DISCUSSION
The top-down proteomic approach used in this study gave
relevant qualitative and quantitative information on the sali-
vary proteome of human preterm newborns. In contrast to
bottom-up proteomic strategies, knowledge of the mass of
the intact protein obtained by MS measurements allows to
discriminate between different isoforms. Clearly, the top-
down strategy used in this study appears the most direct
approach to detect the differences, e.g. between the isoforms
of S100A7 and S100A9 proteins.
It should be mentioned that the proteins characterized in
this study are likely to exert their function throughout a subtle
interplay between monomeric and homo- and hetero-oligo-
meric not-covalent assemblies, which are unstable under the
acidic conditions used during HPLC-ESI-MS analysis. More-
over, the acidic treatment generates a small precipitate, which
in adult whole saliva is mainly constituted by mucins. In the
preterm whole saliva, the precipitate can enclose other pro-
teins relevant for the fetal development, which will be the aim
of future studies.
Saliva is a body fluid of a very complex composition with
fundamental roles in the protection of the mouth and its
annexes during life. Although the precise molecular interplay
between the different salivary adult components is far from
being elucidated, the exploitation of this function is partly
granted by specific peptides and proteins secreted by salivary
glands that could play relevant roles in the protection of the
enamel surface, in the assumption of food and beverage and
in the modulation of the oral flora (1). This protection is not
necessary during fetal life because fetus nutrients are sup-
plied directly by the placental system of the mother and
therefore protected against the threats of external environ-
ment. Until now the fetal mouth has been believed to be a
passive organ reaching the physiological-anatomical matura-
tion mostly following delivery. However, our group recently re-
ported high levels of T4 and T10 in preterm newborn saliva (8).
We were able to show that these peptides in fetuses mainly
originate from salivary gland secretion, in contrast to adult saliva
where low quantities originate from the gingival crevicular fluid
(9). Thus, salivary glandsmay have a specific function during the
intrauterine life. This view is further supported by this study,
where we could show that several other proteins were present
in whole saliva of preterm newborns. Salivary concentration of
these proteins decreased as a function of postconceptional
age, reaching values observed in at term newborns at about 270
FIG. 5. The ratios (XIC peak area)/
(ml of WS) of six proteins from three
preterm newborns (1–3) are reported
as an example of interindividual vari-
ability. Ratios are normalized to highest
value determined for each protein in
each subject in the range of 194–290
days of postconceptional age. SPRR3
data refer to the 17 kDa isoform. PCA,
postconceptional age.
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days of postconceptional age and the values observed in adult
whole saliva later in development.
The decrease of concentration as a function of preterm
newborn age can be partly linked to an increased salivary
flow-rate, which could not be measured for ethical reasons.
However, because the shape of decrease for many proteins
detected in this study was different, the variations are prob-
ably not linked to a dilution process but rather suggest a
coordinate and hierarchical actions of these proteins. The
interindividual variability shown in Fig. 5 most likely is not
linked to feeding habits because of similar nutritional pro-
gram, standardized for all the subjects.
Among the proteins characterized, many are members of
the S100 protein family, which is the largest subgroup within
the superfamily of EF-hand calcium-binding proteins, exclu-
sively expressed in vertebrate (22, 23). A specific feature of
this protein family is that some members are secreted from
cells upon stimulation exerting cytokine- and chemokine-like
extracellular activities via the receptor for advanced glycation
endproducts. Functional diversification of this family of pro-
teins is achieved by specific cell- and tissue-expression pat-
terns, structural variations, different metal-ion binding prop-
erties, as well as by their ability to form homo- and hetero- and
even oligomeric assemblies (24). In this study significant
amounts of S100A7, A8, A9, A11, and A12 were detected in
whole saliva of preterm newborns. Interestingly, the most
abundant S100A7 isoform detected was the D27, with minor
quantities of the E27 isoform. Some of the mass values not
identified could pertain to other S100, such as the protein with
a Mav 10,651  2 Da, which might correspond to S100B or
S100A5. Minute amounts of a protein with a mass of 11,712
2 Da, which might correspond to S100A16, eluting in the
proximity of S100A7, were found in few samples.
The presence of high amounts of two isoforms of SPRR3 in
preterm whole saliva is intriguing, and it may be in some way
related to the S100 family. The molecular mechanisms under-
lying the formation of the epithelial barrier start from the
desmosomal cadherins, that are linked to the keratin cytoskel-
eton via several plaque proteins, such as desmoplakin and
-catenin. However, oral keratinocytes express additional dif-
ferentiation markers, including filaggrinin and tricohyalin,
which associate with the cytoskeleton during terminal differ-
entiation. Moreover, other proteins such as loricrin, involucrin,
and small proline-rich proteins, comprising SPRR3, are cross-
linked into the epithelial envelope by transglutaminases (25).
The presence of SPRR3 in preterm whole saliva could be thus
linked to the inability of immature keratinocytes to cross-link
the protein to the cytoskeleton for a lack of epithelial trans-
FIG. 6. Colored map of the crossed
correlation coefficients (Pearson r)
computed among the 25 proteins of
Table I. The significance at the conven-
tional levels for r values greater than
0.400 is better than p  0.001 (n  61).
The range of r values corresponding to
the different colors is reported on the
right side of the figure. SPRR3 data refer
to both isoforms.
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glutaminase. However, in this study no other proteins of the
cytoskeleton were detected in whole saliva of preterm new-
borns and none of the protein masses waiting for character-
ization seems to correspond to other proteins of the cytoskel-
eton. Free SPRR3 is only detected in highly differentiated
keratinocytes of well-differentiated squamous cell carcino-
mas, indicating that the protein is induced in skin tumors only
when keratinocytes undergo extensive squamous differentia-
tion (26). Furthermore, various authors have suggested that
the proteins of the SPRR3 family (SPR family, pancornulins)
play a relevant “active” role in the formation of cornified
epithelia (27). The correlation between SPRR3, and the pro-
teins of S100 family is interesting, considering that several of
these proteins are related (have an EF-hand structural motif)
and their genes localized in a cluster on human chromosome
1q21, which encodes for this protein (SPRR3) as well as for
S100A7, A8, A9, A10, A11, and loricrin (19, 28, 29). Because
of the presence of different transglutaminase reactive resi-
dues, S100A10 and S100A11 are incorporated into the cor-
nified envelope of keratinocytes (30, 31). The colocalization of
genes expressed during maturation of epidermal cells to-
gether with genes encoding calcium-binding proteins is par-
ticularly intriguing, because calcium levels tightly control the
differentiation of epithelial cells, the expression of genes en-
coding epidermal structural proteins, as well as transglutami-
nase activity. Because of this close functional cooperation,
the cluster 1q21, including these loci, has been proposed to
be a specific gene complex and has been named “epidermal
differentiation complex” (32).
The detection of stefin A and stefin B in whole saliva of
preterm newborns can be related to some recent hypothe-
sized properties of these proteins. Stefins A and B (or cyst-
atins A and B) are indeed the better known members of type
1 cystatin family (cysteine proteinase inhibitors), generically
called stefins (33). Stefins were commonly considered potent
intracellular inhibitors of papain and cathepsins L, S, and H,
but they have also been detected in significant amounts in
different body fluids (33, 34) and recent studies outlined a very
complex set of functions and interplays for them (35). Stefin A
is predominantly present in blood and epithelial cells, partic-
ularly in high amounts in immune follicular dendritic cells,
where it has been speculated that it plays a role in the pre-
vention of apoptosis of B-lymphocytes by inhibition of ca-
thepsin B (36, 37). A recent proteomic study postulated rele-
vant functions of stefin A in mouse neonatal skin during
development and in immune response (38), role probably
related to the significant presence of stefin A found in this
study in preterm whole saliva. Some authors have established
the participation of this protein in the structural organization of
cornified cell envelope too (39).
Stefin B is more widely distributed inside the cytoplasm of
most human cells and increased levels have been described
in a variety of malignant tumors (40). Its gene expression is
increased in human monocytes following stimulation by li-
popolysaccharides (41) and it plays important and composite,
although not defined, roles in neural stem cells and in differ-
entiated neurons and astrocytes (42). Moreover, it is an intra-
cellular modulator of rat bone reabsorption (43). However, a
possible correlation between stefin A and B with other pro-
teins such as SPRR3 and S100 proteins are presently not
known.
Antileukoproteinase could also be involved in the develop-
ment of mucosal epithelia. This protein is an inhibitor of gran-
ulocytic serine proteases, modulating granulocyte-endothe-
lium interaction (44) and it seems involved in the formation of
cartilage, because of its accumulation in normal but not in
arthritic cartilage (45).
T4 and T10 are new entries in the repertoire of adult
salivary proteins and peptides (9, 46). Beta thymosins are
ubiquitous peptides with intra- and extracellular functions (47,
48), although the secretion pathway of these peptides is not
fully understood (49). T4 was shown to modify the rate of
attachment and spreading of endothelial cells on matrix com-
ponents inducing matrix metalloproteinases (50) and to stim-
ulate the migration of human umbilical vein endothelial cells
(51). Although T4 is a potent enhancer of angiogenesis, T10
inhibits it and changes of the two peptides concentration ratio
can exert either positive or negative control (52, 53). As dem-
onstrated by Reti and coworkers (54), T4 plays an important
role in suppressing the production of interleukin-8 following
stimulation by tumor-necrosis factor  and it acts on the
whole as antimicrobial, anti-inflammatory and anti-apo-
ptotic peptide on gingival fibroblasts. The properties of T10
are less known when compared with T4. The results of this
study confirm that the two peptides are present in signifi-
cant amounts in preterm whole saliva, and at variance in
adult saliva, they derive mainly from salivary gland secretion
(8). T4 andT10 could play a role in angiogenesis, which
has also reported for some S100 proteins, mainly S100A4
(for recent review see (55)). The different biological role of
these peptides may be at the basis of the low correlations
observed among the levels of thymosins  and the other
proteins (Fig. 6).
The presence of large amounts of histone H1c in preterm
whole saliva is puzzling. Indeed, in the hypothesis of its re-
lease from cell shedding, other histones should have been
present in saliva. Similar consideration can be made for ly-
sozyme, because its defensive role against pathogens does
not fit with its decrease observed as a function of postcon-
ceptional age. The detection of - and -globins was re-
stricted to samples of all the subjects in the approximate
range of 194–240 days of postconceptional age. Their detec-
tion most probably is because of their release from the pre-
term mucosal epithelium.
Many of the proteins identified in this study are considered
to be tumor markers in the adult. This observation led us to
suppose that during fetal development the interplay between
these proteins might contribute to the molecular events re-
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sponsible for cell growth and death. On the contrary, the
abnormal regulation of their expression in the adult might be
at the basis of anomalous cellular growth and might be con-
nected to the development of different tumors with embryonal
etiology. Moreover, the recognition of tumor stem cells in
many solid cancers has reinvigorated the hypothesis of a
pluripotent stem cell as the cell of origin for cancer (56).
Because these tumor stem cells have direct access to em-
bryologic programs, including the capacity to produce pro-
teins and peptides normally secreted only during intrauterine
life (57), we can speculate that at least a part of the fetal
proteins described in this study, following disappearing in the
postnatal life, could reappear in cancer cells. Preliminary data
from our group on T4 expression in salivary glands’ tumors
and in colon cancer (58) evidenced T4 reactivity in tumor
cells undergoing epithelial-mesenchymal transition, a highly
conserved cellular program typical of several stages of em-
bryonic development as well as of cancer invasion and me-
tastasis (59). This finding seems to further support our
hypothesis.
In conclusion, by analyzing a noninvasive specimen collec-
tion of saliva, this study suggests that the development of
preterm newborns, and fetuses, requires the presence of
distinct proteins of variable amounts at defined stages. Some
of them have been characterized in this study, but others are
waiting for a definitive identification. Further studies will be
conducted to investigate their functions and interplay and to
establish if they derive from gland secretion (as shown for
T4), from the fetal oral epithelium or other sources.
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